Source: UnicoCell

UnicoCell Biomed Co. Ltd. and Dr. RK Tsai of Hualien Tzu-Chi Hospital Ophthalmology Research Center have collaborated on the therapeutic study of treating retinal degenerative diseases with allogeneic mesenchymal stem cells. This pre-clinical research project has received a grant from Frontier Science Research Program (FSP) sponsored by the Ministry of Science and Technology. Press conference was held at Hualien Tzu-Chi Hospital for the signing ceremony of the collaboration on June 23, 2022.

As the rates of visual impairment continue to rise, so does the importance of finding a feasible therapy for retinal degenerative diseases.  Dr. RK Tsai and his team are working together to explore the prospect of applying UnicoCell's  allogeneic stem cell and patented stem cell derived conditioned medium for treatment of retinal degenerative diseases.

UnicoCell has been focused on the development of stem cell technologies and related applications for the past decade and has built a comprehensive cell banks in accordance with the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH). In addition, the company has developed a proprietary process to produce stem cell derived conditioned medium (Patent No. I555847) which can significantly increase the unit concentration of stem cell secretome compared to the traditional culture method. 

UnicoCell believes that with the rigorous study and professional cooperation with Dr. RK Tsai and his team, the result of this therapeutic study of retinal degenerative diseases using clinical quality stem cell product produced by UnicoCell is highly anticipated and will hopefully benefit the population soon.

For more information please visit www.unicocell.com